Aside from macrophages, HSV-MSLN monotherapy and combination therapy significantly increased migratory DCs (XCR1high CD103high) in the tumor compared to control and MSLN-CAR T cells groups at day 3, which was not observed at day 7 (Fig. 6a, b). Here, MSLN is linked to neoplasm.